NanoViricides, Inc. (NNVC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NanoViricides, Inc. on October 11, 2022, covering events occurring on October 6, 2022. The company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol NNVC.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation arrangements.
Material Changes
On October 6, 2022, the company entered into an Extension Agreement with Dr. Anil R. Diwan, extending his role as President through June 30, 2023. Key terms include:
- Base Salary: $400,000 annually.
- Equity Grant: 10,204 shares of Series A Convertible Preferred Stock granted as an incentive.
- Vesting Schedule: The preferred stock vests in equal quarterly installments starting September 30, 2022, with full vesting on June 30, 2023.
- Severance: Eligible for six months' salary if terminated without cause, including continued benefits and bonus eligibility.
- Insurance: A $2 million Term Life Insurance policy is maintained, with $1 million assigned to the company and the remainder to Dr. Diwan's estate.
Outlook, Risks, and Unusual Items
The Series A Preferred Stock granted is non-transferrable and has no trading market. It carries 9 votes per share and is convertible only upon a "change of control" into 3.5 shares of common stock per preferred share. No specific financial guidance or new risk factors were disclosed in this filing.
Investor Verification Checklist
- Verify the full terms of the Employment Agreement and Extension (Exhibits 10.1 and 10.2) for any clauses not summarized in the 8-K.
- Confirm the definition of "change of control" in the Series A Preferred Stock specification to understand conversion triggers.
- Review the company's most recent 10-Q or 10-K for current liquidity status, as this 8-K does not contain financial statements.
- Assess the impact of the $400,000 salary and equity grant on the company's cash burn rate and dilution potential.